Literature DB >> 25002663

Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine.

Pui-Ying Iroh Tam1, Lawrence C Madoff2, Brandon Coombes3, Stephen I Pelton4.   

Abstract

OBJECTIVE: To examine whether there is a different clinical profile and severity of invasive pneumococcal disease (IPD) in children caused by nonvaccine types in the era of 13-valent pneumococcal conjugate vaccine (PCV13).
METHODS: Observational study of childhood IPD in Massachusetts based on state public health surveillance data comparing pre-PCV13 (2007-2009) and post-PCV13 (2010-2012) eras.
RESULTS: There were 168 pre-PCV13 cases of IPD and 85 post-PCV13 cases of IPD in Massachusetts children ≤5 years of age. PCV13 serotypes declined by 18% in the first 2 years after PCV13 use (P = .011). In the post-PCV13 phase, a higher proportion of children were hospitalized (57.6% vs. 50.6%), and a higher proportion of children had comorbidity (23.5% vs. 19.6%). Neither difference was statistically significant, nor were comparisons of IPD caused by vaccine and nonvaccine types. Children with comorbidities had higher rates of IPD caused by a nonvaccine type (27.6% vs. 17.2%; P = .085), were more likely to be hospitalized (80.4% vs. 50%; P < .0001), and were more likely to have a longer hospital stay (median of 3 days vs. 0.5 days; P = .0001).
CONCLUSIONS: Initial data suggest that nonvaccine serotypes are more common in children with underlying conditions, who have greater morbidity from disease. In the post-PCV13 era, a larger proportion of patients are hospitalized, but mortality rates are unchanged. Routine vaccination with PCV13 may not be enough to reduce the risk in patients with comorbidity.
Copyright © 2014 by the American Academy of Pediatrics.

Entities:  

Keywords:  children; comorbidity; conjugate vaccine; invasive pneumococcal disease; severity

Mesh:

Substances:

Year:  2014        PMID: 25002663      PMCID: PMC4187237          DOI: 10.1542/peds.2014-0473

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.

Authors:  David J Farrell; Keith P Klugman; Michael Pichichero
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

2.  The challenge of preventing invasive pneumococcal disease in children with comorbid illnesses.

Authors:  Stephen I Pelton
Journal:  Clin Infect Dis       Date:  2013-12-02       Impact factor: 9.079

3.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Authors:  C G Whitney; M M Farley; J Hadler; L H Harrison; C Lexau; A Reingold; L Lefkowitz; P R Cieslak; M Cetron; E R Zell; J H Jorgensen; A Schuchat
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

4.  Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.

Authors:  Daniel R Feikin; Keith P Klugman
Journal:  Clin Infect Dis       Date:  2002-08-07       Impact factor: 9.079

5.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

6.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

7.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

Authors:  Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney
Journal:  J Infect Dis       Date:  2007-10-04       Impact factor: 5.226

8.  Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia.

Authors:  Andrew P Steenhoff; Samir S Shah; Adam J Ratner; Sujata M Patil; Karin L McGowan
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

9.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

10.  Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children.

Authors:  Daniel R Feikin; Mollie Davis; Okey C Nwanyanwu; Peter N Kazembe; Lawrence M Barat; Avril Wasas; Peter B Bloland; Charles Ziba; Thora Capper; Robin E Huebner; Ben Schwartz; Keith P Klugman; Scott F Dowell
Journal:  Pediatr Infect Dis J       Date:  2003-06       Impact factor: 2.129

View more
  11 in total

Review 1.  Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use.

Authors:  Nicola Principi; Giuseppe Di Cara; Ilaria Bizzarri; Chiara Isidori; Paola Borgia; Costanza Mignini; Marco Saponara; Alberto Argentiero; Susanna Esposito
Journal:  Curr Infect Dis Rep       Date:  2018-01-24       Impact factor: 3.725

2.  Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016.

Authors:  Tolulope A Adebanjo; Tracy Pondo; David Yankey; Holly A Hill; Ryan Gierke; Mirasol Apostol; Meghan Barnes; Susan Petit; Monica Farley; Lee H Harrison; Corinne Holtzman; Joan Baumbach; Nancy Bennett; Suzanne McGuire; Ann Thomas; William Schaffner; Bernard Beall; Cynthia G Whitney; Tamara Pilishvili
Journal:  Pediatrics       Date:  2020-02-13       Impact factor: 7.124

3.  Invasive Disease Caused Simultaneously by Dual Serotypes of Streptococcus pneumoniae.

Authors:  Kedibone Ndlangisa; Mignon du Plessis; Mushal Allam; Nicole Wolter; Linda de Gouveia; Keith P Klugman; Cheryl Cohen; Rebecca A Gladstone; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

4.  Racial and Regional Differences in Rates of Invasive Pneumococcal Disease.

Authors:  Annabelle de St Maurice; Carlos G Grijalva; Christopher Fonnesbeck; William Schaffner; Natasha B Halasa
Journal:  Pediatrics       Date:  2015-10-12       Impact factor: 7.124

5.  [Impact of the 10-valent pneumococcal conjugate vaccine on the southern area of Santiago (Chile), 2009-2015Efeito da vacina pneumocócica 10-valente conjugada na região sul de Santiago, Chile, 2009-2015].

Authors:  Sylvina Alvarado; Gabriel Cavada; Rodolfo Villena; Jan Wilhelm; Isolda Budnik; Cristian Lara; Ximena Salinas; Nury Azpilcueta; María Teresa Valenzuela
Journal:  Rev Panam Salud Publica       Date:  2018-09-24

6.  Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10.

Authors:  Germán Camacho Moreno; Luisa F Imbachi; Aura L Leal; Vivian M Moreno; Jaime A Patiño; Iván F Gutiérrez; Sandra Beltrán; Martha I Álvarez-Olmos; Cristina Mariño; Rocío Barrero; Fabio Espinosa; Nicolás Ramos; Liliana P Castellar; Nella Sánchez; Anita Montañez
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

7.  Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France.

Authors:  Claire Janoir; Agnès Lepoutre; Laurent Gutmann; Emmanuelle Varon
Journal:  Open Forum Infect Dis       Date:  2016-02-02       Impact factor: 3.835

8.  Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013.

Authors:  Eun Young Cho; Eun Hwa Choi; Jin Han Kang; Kyung-Hyo Kim; Dong Soo Kim; Yae-Jean Kim; Young Min Ahn; Byung Wook Eun; Sung Hee Oh; Sung-Ho Cha; Hye-Kyung Cho; Young Jin Hong; Kwang Nam Kim; Nam Hee Kim; Yun-Kyung Kim; Jong-Hyun Kim; Hyunju Lee; Taekjin Lee; Hwang Min Kim; Kun Song Lee; Chun Soo Kim; Su Eun Park; Young Mi Kim; Chi Eun Oh; Sang Hyuk Ma; Dae Sun Jo; Young Youn Choi; Jina Lee; Geun-Ryang Bae; Ok Park; Young-Joon Park; Eun Seong Kim; Hoan Jong Lee
Journal:  J Korean Med Sci       Date:  2016-04-27       Impact factor: 2.153

9.  Evaluation of newborn sickle cell screening programme in England: 2010-2016.

Authors:  Allison Streetly; Rupa Sisodia; Moira Dick; Radoslav Latinovic; Kirsty Hounsell; Elizabeth Dormandy
Journal:  Arch Dis Child       Date:  2017-11-05       Impact factor: 3.791

10.  The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease.

Authors:  Claudia L Gaviria-Agudelo; Alejandro Jordan-Villegas; Carla Garcia; George H McCracken
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.